We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Apricus Biosciences, Inc. | NASDAQ:APRI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.2201 | 0.235 | 0.23 | 0 | 01:00:00 |
|
ý
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
Nevada
|
|
87-0449967
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
Title of Each Class
|
|
Name of Exchange on Which Registered
|
Common Stock, par value $.001
|
|
The NASDAQ Capital Market
|
Large accelerated filer
|
|
o
|
|
|
Accelerated filer
|
|
o
|
Non-accelerated filer
|
|
o
|
(do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
ý
|
Emerging growth company
|
|
o
|
|
|
|
|
|
|
|
|
Page
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
2017 |
|
December 31,
2016 |
||||
|
(Unaudited)
|
|
|
||||
Assets
|
|
|
|
||||
Current assets
|
|
|
|
||||
Cash
|
$
|
3,762
|
|
|
$
|
2,087
|
|
Prepaid expenses and other current assets
|
181
|
|
|
177
|
|
||
Current assets of discontinued operations
|
1,203
|
|
|
1,370
|
|
||
Total current assets
|
5,146
|
|
|
3,634
|
|
||
Property and equipment, net
|
142
|
|
|
164
|
|
||
Other long term assets
|
65
|
|
|
60
|
|
||
Noncurrent assets of discontinued operations
|
—
|
|
|
842
|
|
||
Total assets
|
$
|
5,353
|
|
|
$
|
4,700
|
|
|
|
|
|
||||
Liabilities and stockholders’ deficit
|
|
|
|
||||
Current liabilities
|
|
|
|
||||
Note payable, net
|
$
|
—
|
|
|
$
|
6,650
|
|
Accounts payable
|
485
|
|
|
686
|
|
||
Accrued expenses
|
545
|
|
|
1,236
|
|
||
Accrued compensation
|
738
|
|
|
614
|
|
||
Current liabilities of discontinued operations
|
822
|
|
|
2,108
|
|
||
Total current liabilities
|
2,590
|
|
|
11,294
|
|
||
Warrant liabilities
|
1,854
|
|
|
846
|
|
||
Deferred rent
|
67
|
|
|
76
|
|
||
Total liabilities
|
4,511
|
|
|
12,216
|
|
||
|
|
|
|
||||
Commitments and contingencies
|
|
|
|
||||
Stockholders’ equity (deficit)
|
|
|
|
||||
Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of March 31, 2017 and December 31, 2016
|
$
|
—
|
|
|
$
|
—
|
|
Common stock, $.001 par value, 15,000,000 shares authorized, 7,741,782 and 7,733,205 issued and outstanding as of March 31, 2017 and December 31, 2016, respectively
|
8
|
|
|
8
|
|
||
Additional paid-in-capital
|
309,069
|
|
|
308,784
|
|
||
Accumulated deficit
|
(308,235
|
)
|
|
(316,308
|
)
|
||
Total stockholders’ equity (deficit)
|
842
|
|
|
(7,516
|
)
|
||
Total liabilities and stockholders’ equity (deficit)
|
$
|
5,353
|
|
|
$
|
4,700
|
|
|
Three Months Ended
March 31, |
||||||
|
2017
|
|
2016
|
||||
Operating expense
|
|
|
|
||||
Research and development
|
$
|
412
|
|
|
$
|
2,602
|
|
General and administrative
|
1,441
|
|
|
2,224
|
|
||
Total operating expense
|
1,853
|
|
|
4,826
|
|
||
Loss before other income (expense)
|
(1,853
|
)
|
|
(4,826
|
)
|
||
Other income (expense)
|
|
|
|
||||
Interest expense, net
|
(95
|
)
|
|
(279
|
)
|
||
Loss on extinguishment of debt
|
(422
|
)
|
|
—
|
|
||
Change in fair value of warrant liability
|
(1,008
|
)
|
|
2,800
|
|
||
Other financing expenses
|
—
|
|
|
(205
|
)
|
||
Other expense, net
|
(26
|
)
|
|
(4
|
)
|
||
Total other (expense) income
|
(1,551
|
)
|
|
2,312
|
|
||
Loss from continuing operations
|
(3,404
|
)
|
|
(2,514
|
)
|
||
Income from discontinued operations
|
11,477
|
|
|
9
|
|
||
Net income (loss)
|
$
|
8,073
|
|
|
$
|
(2,505
|
)
|
|
|
|
|
||||
Earnings (loss) per share
|
|
|
|
||||
Continuing operations
|
|
|
|
||||
Basic
|
$
|
(0.44
|
)
|
|
$
|
(0.46
|
)
|
Diluted
|
$
|
(0.44
|
)
|
|
$
|
(0.95
|
)
|
Discontinued operations
|
|
|
|
||||
Basic
|
$
|
1.48
|
|
|
$
|
—
|
|
Diluted
|
$
|
1.48
|
|
|
$
|
—
|
|
Total earnings (loss) per share
|
|
|
|
||||
Basic
|
$
|
1.04
|
|
|
$
|
(0.46
|
)
|
Diluted
|
$
|
1.04
|
|
|
$
|
(0.95
|
)
|
Weighted average common shares outstanding
|
|
|
|
||||
Basic
|
7,737
|
|
|
5,505
|
|
||
Diluted
|
7,737
|
|
|
5,602
|
|
|
|
For the Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2016
|
||||
Cash flows from operating activities:
|
|
|
|
|
||||
Net income (loss)
|
|
$
|
8,073
|
|
|
$
|
(2,505
|
)
|
Net income from discontinued operations
|
|
11,477
|
|
|
9
|
|
||
Net loss from continuing operations
|
|
(3,404
|
)
|
|
(2,514
|
)
|
||
Adjustments to reconcile net income (loss) to net cash used in operating activities from continuing operations:
|
|
|
|
|
||||
Depreciation and amortization
|
|
56
|
|
|
72
|
|
||
Non-cash interest expense
|
|
56
|
|
|
98
|
|
||
Stock-based compensation expense
|
|
284
|
|
|
355
|
|
||
Warrant liabilities revaluation
|
|
1,008
|
|
|
(2,800
|
)
|
||
Loss on debt extinguishment
|
|
422
|
|
|
—
|
|
||
Changes in operating assets and liabilities from continuing operations:
|
|
|
|
|
||||
Prepaid expenses and other current assets
|
|
(4
|
)
|
|
237
|
|
||
Other assets
|
|
(4
|
)
|
|
196
|
|
||
Accounts payable
|
|
(202
|
)
|
|
51
|
|
||
Accrued expenses
|
|
479
|
|
|
(171
|
)
|
||
Accrued compensation
|
|
124
|
|
|
(569
|
)
|
||
Deferred compensation
|
|
—
|
|
|
(45
|
)
|
||
Other liabilities
|
|
(7
|
)
|
|
25
|
|
||
Net cash used in operating activities from continuing operations
|
|
(1,192
|
)
|
|
(5,065
|
)
|
||
Cash flows from investing activities from continuing operations:
|
|
|
|
|
||||
Purchase of fixed assets, net
|
|
—
|
|
|
(6
|
)
|
||
Release of restricted cash
|
|
—
|
|
|
100
|
|
||
Net cash provided by investing activities from continuing operations
|
|
—
|
|
|
94
|
|
||
Cash flows from financing activities from continuing operations:
|
|
|
|
|
||||
Issuance of common stock and warrants, net of offering costs
|
|
—
|
|
|
9,947
|
|
||
Repayment of capital lease obligations
|
|
—
|
|
|
(1
|
)
|
||
Repayment of notes payable
|
|
(7,129
|
)
|
|
(755
|
)
|
||
Net cash (used in) provided by financing activities from continuing operations
|
|
(7,129
|
)
|
|
9,191
|
|
||
Cash flows from discontinued operations:
|
|
|
|
|
||||
Net cash used in operating activities of discontinued operations
|
|
(1,504
|
)
|
|
(1,200
|
)
|
||
Net cash provided by investing activities of discontinued operations
|
|
11,500
|
|
|
—
|
|
||
Net cash provided by (used in) discontinued operations
|
|
9,996
|
|
|
(1,200
|
)
|
||
Net increase in cash
|
|
1,675
|
|
|
3,020
|
|
||
Cash, beginning of period
|
|
2,087
|
|
|
3,887
|
|
||
Cash, end of period
|
|
$
|
3,762
|
|
|
$
|
6,907
|
|
Supplemental disclosure of cash flow information:
|
|
|
|
|
||||
Cash paid for interest
|
|
92
|
|
|
185
|
|
||
Non-cash investing and financing activities:
|
|
|
|
|
||||
Issuance of restricted stock
|
|
—
|
|
|
249
|
|
||
Capital lease payable
|
|
—
|
|
|
(1
|
)
|
||
Purchase of fixed assets not yet paid
|
|
—
|
|
|
(12
|
)
|
||
Accrued transaction costs for 2016 financing activities
|
|
—
|
|
|
(137
|
)
|
|
|
Common
Stock (Shares) |
|
Common
Stock (Amount) |
|
Additional
Paid-In Capital |
|
Accumulated
Deficit |
|
Total
Stockholders’ Equity (Deficit) |
|||||||||
Balance as of December 31, 2016
|
|
7,733
|
|
|
$
|
8
|
|
|
$
|
308,784
|
|
|
$
|
(316,308
|
)
|
|
$
|
(7,516
|
)
|
Stock-based compensation expense
|
|
—
|
|
|
—
|
|
|
285
|
|
|
—
|
|
|
285
|
|
||||
Issuance of common stock due to the vesting of restricted stock
|
|
9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Net income
|
|
—
|
|
|
—
|
|
|
—
|
|
|
8,073
|
|
|
8,073
|
|
||||
Balance as of March 31, 2017
|
|
7,742
|
|
|
$
|
8
|
|
|
$
|
309,069
|
|
|
$
|
(308,235
|
)
|
|
$
|
842
|
|
•
|
its ability to raise additional funds to finance its operations;
|
•
|
its ability to maintain compliance with the listing requirements of The NASDAQ Capital Market;
|
•
|
the timing and outcome of the Company’s new drug application (“NDA”), resubmission for Vitaros, and any additional development requirements imposed by the U.S. Food and Drug Administration (“FDA”) in connection with such resubmission;
|
•
|
the outcome, costs and timing of clinical trial results for its product candidates;
|
•
|
the extent and amount of any indemnification claims made by Ferring under the Ferring Asset Purchase Agreement;
|
•
|
the emergence and effect of competing or complementary products;
|
•
|
its ability to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;
|
•
|
its ability to retain its current employees and the need and ability to hire additional management and scientific and medical personnel;
|
•
|
the terms and timing of any collaborative, licensing or other arrangements that it has or may establish;
|
•
|
the restrictions from using the Company’s committed equity facility with Aspire Capital until April 2018;
|
•
|
the trading price of the Company’s common stock being above the
$1.00
closing floor price that is required for the Company to use the committed equity financing facility with Aspire Capital when it becomes available in April 2018;
|
•
|
the trading price of its common stock; and
|
•
|
its ability to increase the number of authorized shares outstanding to facilitate future financing events.
|
|
|
Quoted Market Prices for Identical Assets
(Level 1) |
|
Significant Other
Observable Inputs (Level 2) |
|
Significant
Unobservable Inputs (Level 3) |
|
Total
|
||||||||
Warrant liabilities
|
|
|
|
|
|
|
|
|
||||||||
Balance as of March 31, 2017
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,854
|
|
|
$
|
1,854
|
|
Balance as of December 31, 2016
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
846
|
|
|
$
|
846
|
|
|
|
March 31, 2017
|
|
December 31, 2016
|
||||
Risk-free interest rate
|
|
1.64%-1.98%
|
|
|
1.64%-1.99%
|
|
||
Volatility
|
|
83.4%-89.98%
|
|
|
77.25%-81.03%
|
|
||
Dividend yield
|
|
—
|
%
|
|
—
|
%
|
||
Expected term
|
|
4.5-5.93
|
|
|
4.75-6.17
|
|
||
Weighted average fair value
|
|
$
|
1.07
|
|
|
$
|
0.49
|
|
|
|
Warrant liabilities
|
||
Balance as of December 31, 2016
|
|
$
|
846
|
|
Change in fair value measurement of warrant liability
|
|
1,008
|
|
|
Balance as of March 31, 2017
|
|
$
|
1,854
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2016
|
||||
Basic net loss per share from continuing operations
|
|
|
|
|
||||
Net loss allocated to common stockholders
|
|
(3,404
|
)
|
|
(2,514
|
)
|
||
Weighted average common shares outstanding- basic
|
|
7,737
|
|
|
5,505
|
|
||
Net loss per share from continuing operations - basic
|
|
$
|
(0.44
|
)
|
|
$
|
(0.46
|
)
|
Diluted net loss per share from continuing operations
|
|
|
|
|
||||
Net loss allocated to common stockholders- basic
|
|
$
|
(3,404
|
)
|
|
$
|
(2,514
|
)
|
Change in fair value of warrants
|
|
—
|
|
|
$
|
2,800
|
|
|
Net loss allocated to common stockholders
|
|
$
|
(3,404
|
)
|
|
$
|
(5,314
|
)
|
Weighted average common shares outstanding- basic
|
|
7,737
|
|
|
$
|
5,505
|
|
|
Dilutive securities
|
|
—
|
|
|
97
|
|
||
Weighted average common shares outstanding- diluted
|
|
7,737
|
|
|
5,602
|
|
||
Net loss per share from continuing operations - diluted
|
|
$
|
(0.44
|
)
|
|
$
|
(0.95
|
)
|
|
|
As of March 31,
|
||||
|
|
2017
|
|
2016
|
||
Outstanding stock options
|
|
406,825
|
|
|
552,817
|
|
Outstanding warrants
|
|
2,070,932
|
|
|
1,354,783
|
|
Restricted stock
|
|
585,500
|
|
|
22,468
|
|
|
|
March 31, 2016
|
||
Risk-free interest rate
|
|
1.57%-1.78%
|
|
|
Volatility
|
|
72.35%-80.02%
|
|
|
Dividend yield
|
|
—
|
%
|
|
Expected term
|
|
5.25-6.08 years
|
|
|
Forfeiture rate
|
|
11.33
|
%
|
|
Weighted average grant date fair value
|
|
$
|
7.60
|
|
|
|
Number of
Shares |
|
Weighted
Average Exercise Price |
|||
Outstanding as of December 31, 2016
|
|
415
|
|
|
$
|
17.23
|
|
Cancelled
|
|
(8
|
)
|
|
$
|
15.23
|
|
Outstanding as of March 31, 2017
|
|
407
|
|
|
$
|
17.27
|
|
|
|
Number of
Shares |
|
Weighted Average Grant Date Fair Value
|
|||
Unvested as of December 31, 2016
|
|
115
|
|
|
$
|
5.11
|
|
Granted
|
|
485
|
|
|
$
|
1.28
|
|
Vested
|
|
(15
|
)
|
|
$
|
11.10
|
|
Unvested as of March 31, 2017
|
|
586
|
|
|
$
|
1.79
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2016
|
||||
Research and development
|
|
$
|
52
|
|
|
$
|
64
|
|
General and administrative
|
|
232
|
|
|
291
|
|
||
Total
|
|
$
|
284
|
|
|
$
|
355
|
|
Upfront payment received
|
$
|
11,500
|
|
Payment receivable
|
709
|
|
|
Total proceeds from sale
|
$
|
12,209
|
|
Carrying value of assets sold in sale
|
(1,578
|
)
|
|
Liabilities transferred upon sale
|
1,186
|
|
|
Total gain on sale of Purchased Assets
|
$
|
11,817
|
|
|
March 31,
2017 |
|
December 31,
2016 |
||||
Accounts receivable
|
$
|
348
|
|
|
$
|
530
|
|
Inventories
|
—
|
|
|
764
|
|
||
Prepaid expenses and other current assets
|
855
|
|
|
76
|
|
||
Current assets of discontinued operations
|
1,203
|
|
|
1,370
|
|
||
Property and equipment, net
|
—
|
|
|
842
|
|
||
Total assets of discontinued operations
|
$
|
1,203
|
|
|
$
|
2,212
|
|
|
|
|
|
||||
Accounts payable
|
241
|
|
|
274
|
|
||
Accrued expenses
|
581
|
|
|
1,834
|
|
||
Total liabilities of discontinued operations
|
$
|
822
|
|
|
$
|
2,108
|
|
|
Three Months Ended
March 31, |
||||||
|
2017
|
|
2016
|
||||
Product sales
|
$
|
143
|
|
|
$
|
259
|
|
Royalty revenue
|
221
|
|
|
367
|
|
||
Cost of goods sold
|
(74
|
)
|
|
(233
|
)
|
||
Operating expenses
|
(614
|
)
|
|
(384
|
)
|
||
Other expense
|
(16
|
)
|
|
—
|
|
||
Gain on sale
|
11,817
|
|
|
—
|
|
||
Income from discontinued operations
|
$
|
11,477
|
|
|
$
|
9
|
|
|
March 31,
2017 |
|
December 31,
2016 |
||||
Professional fees
|
$
|
315
|
|
|
$
|
783
|
|
Deferred compensation
|
90
|
|
|
134
|
|
||
Outside research and development services
|
11
|
|
|
142
|
|
||
Other
|
129
|
|
|
177
|
|
||
|
$
|
545
|
|
|
$
|
1,236
|
|
|
|
December 31,
2016 |
||
Notes payable, principal
|
|
$
|
6,392
|
|
Add: accretion of final payment fee
|
|
378
|
|
|
Less: unamortized debt discount
|
|
(120
|
)
|
|
|
|
6,650
|
|
|
Less: current portion of notes payable, net
|
|
(6,650
|
)
|
|
|
|
$
|
—
|
|
|
Common Shares
Issuable upon Exercise |
|
Weighted
Average Exercise Price |
|
Weighted
Average Remaining Contractual Life (in years) |
||||
Outstanding at December 31, 2016
|
2,317,846
|
|
|
$
|
15.19
|
|
|
4.6
|
|
Cancelled
|
(246,914
|
)
|
|
52.50
|
|
|
—
|
|
|
Outstanding as of March 31, 2017
|
2,070,932
|
|
|
$
|
10.74
|
|
|
4.8
|
|
Exercisable as of March 31, 2017
|
2,070,932
|
|
|
$
|
10.74
|
|
|
4.8
|
|
Shares Issuable Upon Exercise
|
|
Exercise Price
|
|
Expiration Date
|
|||
300,000
|
|
|
$
|
34.00
|
|
|
May 2018
|
54,123
|
|
|
$
|
4.31
|
|
|
September 2021
|
811,802
|
|
|
$
|
4.50
|
|
|
March 2022
|
428,620
|
|
|
$
|
8.80
|
|
|
January 2023
|
441,763
|
|
|
$
|
8.80
|
|
|
March 2023
|
19,380
|
|
|
$
|
12.90
|
|
|
October 2024
|
15,244
|
|
|
$
|
16.40
|
|
|
July 2025
|
2,070,932
|
|
|
|
|
|
ITEM 2.
|
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
•
|
our ability to raise additional funds to finance our operations;
|
•
|
our ability to maintain compliance with the listing requirements of The NASDAQ Capital Market;
|
•
|
the timing and outcome of our new drug application (“NDA”) resubmission for Vitaros, and any additional development requirements imposed by the U.S. Food and Drug Administration (“FDA”) in connection with such resubmission;
|
•
|
the outcome, costs and timing of clinical trial results for our product candidates;
|
•
|
the extent and amount of any indemnification claims made by Ferring under the Ferring Asset Purchase Agreement;
|
•
|
the emergence and effect of competing or complementary products;
|
•
|
our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;
|
•
|
our ability to retain our current employees and the need and ability to hire additional management and scientific and medical personnel;
|
•
|
the terms and timing of any collaborative, licensing or other arrangements that we have or may establish;
|
•
|
the restrictions from using our committed equity financing facility with Aspire Capital until April 2018;
|
•
|
the trading price of our common stock being above the
$1.00
closing floor price that is required for us to use the committed equity financing facility with Aspire Capital and the restrictions from using such facility when it becomes available in April 2018;
|
•
|
the trading price of our common stock; and
|
•
|
our ability to increase the number of authorized shares outstanding to facilitate future financing events.
|
|
|
Three Months Ended
March 31, |
|
2017 vs 2016
|
|||||||||||
|
|
2017
|
|
2016
|
|
$ Change
|
|
% Change
|
|||||||
Operating expense
|
|
|
|
|
|
|
|
|
|||||||
Research and development
|
|
$
|
412
|
|
|
$
|
2,602
|
|
|
$
|
(2,190
|
)
|
|
(84
|
)%
|
General and administrative
|
|
1,441
|
|
|
2,224
|
|
|
(783
|
)
|
|
(35
|
)%
|
|||
Total operating expense
|
|
1,853
|
|
|
4,826
|
|
|
(2,973
|
)
|
|
(62
|
)%
|
|||
Loss from operations
|
|
$
|
(1,853
|
)
|
|
$
|
(4,826
|
)
|
|
$
|
2,973
|
|
|
(62
|
)%
|
|
|
Three Months Ended
March 31, |
|
2017 vs 2016
|
|||||||||||
|
|
2017
|
|
2016
|
|
$ Change
|
|
% Change
|
|||||||
Other (expense) income
|
|
|
|
|
|
|
|
|
|||||||
Interest expense, net
|
|
$
|
(95
|
)
|
|
$
|
(279
|
)
|
|
$
|
184
|
|
|
(66
|
)%
|
Loss on extinguishment of debt
|
|
(422
|
)
|
|
—
|
|
|
(422
|
)
|
|
N/M
|
|
|||
Change in fair value of warrant liability
|
|
(1,008
|
)
|
|
2,800
|
|
|
(3,808
|
)
|
|
(136
|
)%
|
|||
Other financing expenses
|
|
—
|
|
|
(205
|
)
|
|
205
|
|
|
(100
|
)%
|
|||
Other expense, net
|
|
(26
|
)
|
|
(4
|
)
|
|
(22
|
)
|
|
550
|
%
|
|||
Total other (expense) income
|
|
$
|
(1,551
|
)
|
|
$
|
2,312
|
|
|
$
|
(3,863
|
)
|
|
(167
|
)%
|
|
Three Months Ended
March 31, |
||||||
|
2017
|
|
2016
|
||||
Product sales
|
$
|
143
|
|
|
$
|
259
|
|
Royalty revenue
|
221
|
|
|
367
|
|
||
Cost of goods sold
|
(74
|
)
|
|
(233
|
)
|
||
Operating expenses
|
(614
|
)
|
|
(384
|
)
|
||
Other expense
|
(16
|
)
|
|
—
|
|
||
Gain on sale
|
11,817
|
|
|
—
|
|
||
Income from discontinued operations
|
$
|
11,477
|
|
|
$
|
9
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2017
|
|
2016
|
||||
Net cash used in operating activities from continuing operations
|
|
$
|
(1,192
|
)
|
|
$
|
(5,065
|
)
|
Net cash provided by investing activities from continuing operations
|
|
—
|
|
|
94
|
|
||
Net cash (used in) provided by financing activities from continuing operations
|
|
(7,129
|
)
|
|
9,191
|
|
||
Net cash provided by (used in) discontinued operations
|
|
9,996
|
|
|
(1,200
|
)
|
||
Net increase in cash
|
|
$
|
1,675
|
|
|
$
|
3,020
|
|
ITEM 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
ITEM 4.
|
CONTROLS AND PROCEDURES
|
•
|
Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
|
•
|
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
|
•
|
Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.
|
•
|
collaborators may not have sufficient resources or may decide not to devote the necessary resources due to internal constraints such as budget limitations, lack of human resources, or a change in strategic focus;
|
•
|
collaborators may believe our intellectual property is not valid or is unenforceable or the product candidate infringes on the intellectual property rights of others;
|
•
|
collaborators may dispute their responsibility to conduct development and commercialization activities pursuant to the applicable collaboration, including the payment of related costs or the division of any revenues;
|
•
|
collaborators may decide to pursue a competitive product developed outside of the collaboration arrangement;
|
•
|
collaborators may not be able to obtain, or believe they cannot obtain, the necessary regulatory approvals;
|
•
|
collaborators may delay the development or commercialization of our product candidates in favor of developing or commercializing their own or another party’s product candidate; or
|
•
|
collaborators may decide to terminate or not to renew the collaboration for these or other reasons.
|
•
|
difficulties in achieving identified financial revenue synergies, growth opportunities, operating synergies and cost savings;
|
•
|
difficulties in assimilating the personnel, operations and products of an acquired company, and the potential loss of key employees;
|
•
|
difficulties in consolidating information technology platforms, business applications and corporate infrastructure;
|
•
|
difficulties in integrating our corporate culture with local customs and cultures;
|
•
|
possible overlap between our products or customers and those of an acquired entity that may create conflicts in relationships or other commitments detrimental to the integrated businesses;
|
•
|
our inability to achieve expected revenues and gross margins for any products we may acquire;
|
•
|
the diversion of management’s attention from other business concerns;
|
•
|
risks and challenges of entering or operating in markets in which we have limited or no prior experience, including the unanticipated effects of export controls, exchange rate fluctuations, foreign legal and regulatory requirements, and foreign political and economic conditions; and
|
•
|
difficulties in reorganizing, winding-down or liquidating operations if not successful.
|
•
|
an annual, nondeductible fee payable by any entity that manufactures or imports specified branded prescription drugs and biologic agents;
|
•
|
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
|
•
|
a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;
|
•
|
a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries under their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D;
|
•
|
extension of manufacturers’ Medicaid rebate liability to individuals enrolled in Medicaid managed care organizations;
|
•
|
expansion of eligibility criteria for Medicaid programs;
|
•
|
expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
|
•
|
a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.
|
•
|
the availability of financial resources for us to commence and complete our planned clinical trials;
|
•
|
reaching agreement on acceptable terms and pricing with prospective contract research organizations (“CROs”) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;
|
•
|
obtaining independent institutional review board (“IRB”) approval at each clinical trial site;
|
•
|
obtaining regulatory approval to commence clinical trials in each country;
|
•
|
recruiting a sufficient number of eligible patients to participate in a clinical trial;
|
•
|
having patients complete a clinical trial or return for post-treatment follow-up;
|
•
|
clinical trial sites deviating from trial protocol or dropping out of a trial;
|
•
|
adding new clinical trial sites; or
|
•
|
manufacturing sufficient quantities of our product candidate for use in clinical trials.
|
•
|
the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
|
•
|
we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of the proposed indications;
|
•
|
the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;
|
•
|
we may be unable to demonstrate that our product candidates’ clinical and other benefits outweigh their safety risks;
|
•
|
the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
|
•
|
the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;
|
•
|
the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;
|
•
|
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval; and
|
•
|
even after following regulatory guidance or advice, the FDA or comparable foreign regulatory authorities may still reject our ultimate regulatory submissions since their guidance is generally considered non-binding and the regulatory authorities have the authority to revise or adopt new and different guidance at any time.
|
•
|
restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;
|
•
|
fines, warning letters or holds on clinical trials;
|
•
|
refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;
|
•
|
product seizure or detention, or refusal to permit the import or export of our product candidates; and
|
•
|
injunctions or the imposition of civil or criminal penalties.
|
•
|
the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;
|
•
|
the federal False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;
|
•
|
the federal HIPAA imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;
|
•
|
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
|
•
|
the federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other “transfers of value” made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to the government ownership and investment interests held by the physicians described above and their immediate family members and payments or other “transfers of value” to such physician owners (manufacturers are required to submit reports to the government by the 90
th
day of each calendar year); and
|
•
|
analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
|
•
|
regulatory authorities may withdraw approvals of such product;
|
•
|
regulatory authorities may require additional warnings on the label;
|
•
|
we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;
|
•
|
we could be sued and held liable for harm caused to patients; and
|
•
|
our reputation may suffer.
|
ITEM 6.
|
EXHIBITS
|
EXHIBITS
NO. |
|
DESCRIPTION
|
|
|
|
2.1†
|
|
Stock Purchase Agreement, dated December 15, 2011, by and among Apricus Biosciences Inc., TopoTarget A/S, and TopoTarget USA, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2012).
|
|
|
|
2.2
|
|
Stock Contribution Agreement, dated June 19, 2012, by and among Apricus Biosciences, Inc., Finesco SAS, Scomedica SA and the shareholders of Finesco named therein (incorporated herein by reference to Exhibit 2.1 to the Company’s Current Report Form 8-K filed with the Securities and Exchange Commission on July 13, 2012).
|
|
|
|
2.3†
|
|
Asset Purchase Agreement by and between Apricus Pharmaceuticals USA, Inc. and Biocodex, Inc., dated March 26, 2013 (incorporated herein by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2013).
|
|
|
|
2.4
|
|
Amendment to Stock Purchase Agreement, dated June 13, 2014, by and between Apricus Biosciences, Inc. and Samm Solutions, Inc. (doing business as BTS Research and formerly doing business as BioTox Sciences) (incorporated herein by reference to Exhibit 2.1 to the Company’s Form 10-Q filed with Securities and Exchange Commission on August 11, 2014).
|
|
|
|
3.1
|
|
Amended and Restated Articles of Incorporation of Apricus Biosciences, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company’s Registration Statement on Form 10-SB filed with the Securities and Exchange Commission on March 14, 1997).
|
|
|
|
3.2
|
|
Certificate of Amendment to Articles of Incorporation of Apricus Biosciences, Inc., dated June 22, 2000 (incorporated herein by reference to Exhibit 3.2 to the Company’s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003).
|
3.3
|
|
Certificate of Amendment to Articles of Incorporation of Apricus Biosciences, Inc., dated June 14, 2005 (incorporated herein by reference to Exhibit 3.4 to the Company’s Form 10-K filed with the Securities and Exchange Commission on March 16, 2006).
|
|
|
|
3.4
|
|
Certificate of Amendment to Amended and Restated Articles of Incorporation of Apricus Biosciences, Inc., dated March 3, 2010 (incorporated herein by reference to Exhibit 3.6 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010).
|
|
|
|
3.5
|
|
Certificate of Correction to Certificate of Amendment to Amended and Restated Articles of Incorporation of Apricus Biosciences, Inc., dated March 3, 2010 (incorporated herein by reference to Exhibit 3.7 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010).
|
3.6
|
|
Certificate of Designation for Series D Junior-Participating Cumulative Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-A12GK filed with the Securities and Exchange Commission on March 24, 2011).
|
|
|
|
3.7
|
|
Certificate of Change filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 17, 2010).
|
|
|
3.8
|
|
Certificate of Amendment to Amended and Restated Articles of Incorporation of Apricus Biosciences, Inc., dated September 10, 2010 (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 10, 2010).
|
|
|
|
3.9
|
|
Certificate of Change filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.1 to the Company’s Form 8-K filed with the Securities and Exchange Commission on October 25, 2016).
|
|
|
|
3.10
|
|
Fourth Amended and Restated Bylaws, dated December 18, 2012 (incorporated herein by reference to Exhibit 3.9 to the Company’s Form 10-K filed with the Securities and Exchange Commission on March 18, 2013).
|
|
|
|
3.11
|
|
Certificate of Withdrawal of Series D Junior Participating Cumulative Preferred Stock, dated May 15, 2013 (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 16, 2013).
|
|
|
|
3.12
|
|
Amendment to the Fourth Amended and Restated Bylaws of Apricus Biosciences, Inc., dated January 11, 2016 (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2016).
|
|
|
|
3.13
|
|
Second Amendment to the Fourth Amended and Restated Bylaws of Apricus Biosciences, Inc., dated March 3, 2016 (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2016).
|
|
|
|
4.1
|
|
Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2011).
|
|
|
|
4.2
|
|
Form of Warrant (incorporated herein by reference to Exhibit 1.1 to the Company’s Current Report on From 8-K filed with the Securities and Exchange Commission on May 24, 2013).
|
|
|
|
4.3
|
|
Form of Warrant issued to the lenders under the Loan and Security Agreement, dated as of October 17, 2014, by and among Apricus Biosciences, Inc., NexMed (U.S.A.), Inc., NexMed Holdings, Inc. and Apricus Pharmaceuticals USA, Inc., as borrowers, Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time including Oxford Finance LLC and Silicon Valley Bank. (incorporated herein by reference to Exhibit 4.2 to the Company’s Form 8-K filed with the Securities and Exchange Commission on October 20, 2014).
|
|
|
|
4.4
|
|
Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2015).
|
|
|
|
4.5
|
|
Form of Warrant issued to Sarissa Capital Domestic Fund LP and Sarissa Capital Offshore Master Fund LP (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2016).
|
|
|
|
4.6
|
|
Form of Warrant issued to other purchasers (incorporated herein by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2016).
|
|
|
|
4.7
|
|
Form of Warrant Amendment (incorporated herein by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2016).
|
|
|
|
4.8
|
|
Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2016).
|
|
|
|
4.9
|
|
Form of Warrant Amendment (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 21, 2017).
|
10.1
|
|
Asset Purchase Agreement, dated March 8, 2017, by and between Ferring International Center S.A. and Apricus Biosciences, Inc., NexMed (U.S.A.), Inc., NexMed Holdings, Inc. and NexMed International Limited (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 8, 2017).
|
|
|
|
10.2
|
|
License Agreement, dated March 8, 2017, by and between Apricus Biosciences, Inc. and Ferring International Center S.A. (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 8, 2017).
|
|
|
|
10.3
|
|
Transition Services Agreement, dated March 8, 2017, by and between Apricus Biosciences, Inc. and Ferring International Center S.A. (incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 8, 2017).
|
31.1
|
|
Certification of Principal Executive Officer and Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
32.1
|
|
Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
101.INS
|
|
XBRL Instance Document. (1)
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema. (1)
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase. (1)
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase. (1)
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase. (1)
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase. (1)
|
(1)
|
Furnished, not filed.
|
|
Apricus Biosciences, Inc.
|
|
|
Date: May 11, 2017
|
/s/ RICHARD W. PASCOE
|
|
Richard W. Pascoe
|
|
Chief Executive Officer and Secretary
|
1 Year Apricus Biosciences, Inc. Chart |
1 Month Apricus Biosciences, Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions